1 / 21

Microsatellite Instability in Sporadic Colorectal Cancer: A Retrospective Study

Microsatellite Instability in Sporadic Colorectal Cancer: A Retrospective Study. Kimberley Slowther Trainee Project West Midlands Regional Genetics Laboratory. Colorectal Cancer. 35,000 diagnosed per year Treatment and prognosis depend upon tumour stage. Causes of CRC. Sporadic 75%.

talasi
Download Presentation

Microsatellite Instability in Sporadic Colorectal Cancer: A Retrospective Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Microsatellite Instability in Sporadic Colorectal Cancer: A Retrospective Study Kimberley Slowther Trainee Project West Midlands Regional Genetics Laboratory

  2. Colorectal Cancer • 35,000 diagnosed per year • Treatment and prognosis depend upon tumour stage

  3. Causes of CRC Sporadic 75% Familial 19% Rare Syndromes <1% HNPCC 5% FAP 1%

  4. Genetic Pathways in CRC • Microsatellite Instability (MSI-H) • Deficiency in DNA mismatch repair (MMR) • HNPCC (MSH2, MLH1, MSH6, PMS2) • 15% sporadic (hypermethylation of MLH1 promoter) • Chromosomal Instability (CIN) • APC, TP53, KRAS, Loss of Heterozygosity, aneuploid DNA content • CpG Island Methylator Phenotype (CIMP) • Methylation of CpG islands in promoter regions of tumour suppressor genes • Sporadic CRCs demonstrating MSI are a subset

  5. Normal Normal Tumour Tumour Microsatellite Instability

  6. Comparison of Sporadic MSI-H with HNPCC Tumours • Both are MSI-H and proximally located • BUT Sporadic MSI-H:- • Greater predilection for the proximal colon • Higher frequency of BRAF mutations • Lower frequency of KRAS mutations • More age related • More common in females • Originate from serrated polyps • HNPCC tumours originate from adenomas

  7. RAS-RAF-MEK-ERK Pathway Regulates growth, differentiation and apoptosis KRAS • GTPase • 90% mutations in codons 12 and 13 • 30-40% sporadic MSS CRC • 40% HNPCC BRAF • Serine-threonine specific kinase • 40% sporadic MSI-H tumours • Not present in HNPCC • Common mutation (90%) is V600E

  8. MSI and Prognosis • MSI in CRC is a positive prognostic indicator • Better five-year rate of overall survival than MSS tumours • Less likely to metastasise • Why? • Enhanced mutation rate induces a burden not compatible with tumour cell survival • Abnormal peptides produced elicit antitumour immune responses that limit tumour growth

  9. Treatment of CRC • Dictated by stage • Stage I: surgery alone • Stage II, III+IV: adjuvant therapy • Less clear cut with Stage II • Patients reviewed on individual basis • Chemotherapy Drugs • 5-fluorouracil/folinic acid (5FU/FA) to Stage II and III patients • 5FU/FA and Oxaliplatin to Stage IV and fitter Stage II and III patients

  10. MSI and Chemotherapy • Resistance of MSI-H CRC to 5FU is well documented • MSS patients have increased survival with 5FU • MSI-H patients do not have improved survival following treatment • Why have 5FU treatment if there is no benefit? • Oxaliplatin therapy not affected by loss of MMR • Information about MSI status could impact treatment:- • Decision of whether or not to opt for adjuvant therapy • Allocation patients to oxaliplatin therapy

  11. Project Aim Investigate whether microsatellite analysis of sporadic colorectal cancer would be a valuable service to offer in future in order to tailor patient treatment

  12. Methods • MSI status of patients with locally advanced, treatable sporadic (absence of family history) CRC • 41 – Department of Surgery Epithelial Research Group • 32 – Department of Histopathology • 7 microsatellite markers • MSI-H if instability present at 2 or more markers • MSI-L if instability present at 1 marker • Analysed MSI data in relation to:- • Age at diagnosis • Gender • BRAF exon 15 mutation • KRAS codon 12 and 13 mutation (41/73) • Tumour site • Tumour differentiation

  13. Results: Microsatellite Status and Age Plus-minus values are means ±SD. • On average patients demonstrating MSI in their tumours were younger but this was not statistically significant • Of the 14 patient samples demonstrating MSI, 7 were older than 70 at diagnosis • Usually opt not to be treated with adjuvant therapy; MSI status could be used to help make this decision

  14. Results: Microsatellite Status and Gender • More female samples demonstrated MSI-H but this was not statistically significant

  15. Results: Microsatellite Status and Tumour Differentiation • MSI-H tumours more poorly differentiated than MSS or MSI-L tumours

  16. Results: Microsatellite Status and Tumour Site • MSI-H associated with localisation of tumour to the proximal colon

  17. Results: Microsatellite Status and BRAF/KRAS Mutations • KRAS mutations and BRAF mutations were mutually exclusive • MSS and MSI-L tumours had a higher frequency of KRAS mutations • MSI-H tumours higher frequency of BRAF mutations

  18. Discussion • What are the benefits of MSI analysis for sporadic CRC? • Improved patient care • MSI-H not given unnecessary treatment (5-FU) • MSI-H allocated to more effective treatments (Oxaliplatin) • ? Cost Benefit • Reduced chemotherapy? • Perhaps not all tumours were sporadic • Ethical Implications • Possibility that HNPCC patients included • Only 14% MSI-H samples contained BRAF mutations • Recommend that patients are counselled

  19. Future Developments • Prospective study • Treatment vs no treatment • ? Unethical • Complicated by wide use of oxaliplatin • Oxaliplatin vs 5FU • In the future just offer oxaliplatin therapy to MSI-H patients

  20. Conclusion • Techniques available to put a system into place to offer MSI analysis of sporadic colorectal tumours • Tailor patient treatment depending upon tumour stage, microsatellite status and age

  21. Acknowledgements • West Midlands Regional Genetics Laboratory • Fiona Macdonald • Jennie Bell • Kerry Wall • University of Birmingham Department of Surgery Epithelial Research Group • Dion Morton • Germaine Caldwell • University Hospital of Birmingham Histopathology Department • Philippe Taniere • Brendan O’Sullivan • Graham Caine

More Related